Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibromyalgia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Fibromyalgia - Pipeline Review, H1 2015', provides an overview of the Fibromyalgia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fibromyalgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Fibromyalgia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fibromyalgia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fibromyalgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fibromyalgia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibromyalgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Fibromyalgia Overview 7 Therapeutics Development 8 Pipeline Products for Fibromyalgia - Overview 8 Pipeline Products for Fibromyalgia - Comparative Analysis 9 Fibromyalgia - Therapeutics under Development by Companies 10 Fibromyalgia - Therapeutics under Investigation by Universities/Institutes 12 Fibromyalgia - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Fibromyalgia - Products under Development by Companies 16 Fibromyalgia - Products under Investigation by Universities/Institutes 17 Fibromyalgia - Companies Involved in Therapeutics Development 18 Collegium Pharmaceutical, Inc. 18 Daiichi Sankyo Company, Limited 19 Eli Lilly and Company 20 Merck & Co., Inc. 21 Sumitomo Dainippon Pharma Co., Ltd. 22 SWITCH Biotech LLC 23 Tonix Pharmaceuticals Holding Corp. 24 Zynerba Pharmaceuticals, Inc. 25 Fibromyalgia - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 droxidopa - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 duloxetine hydrochloride DR - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 milnacipran hydrochloride - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 mirogabalin - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 mirtazapine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 naltrexone - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 PRTT-200 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 SWT-06101 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 TD-9855 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 TNX-102 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 ZYN-001 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Fibromyalgia - Recent Pipeline Updates 53 Fibromyalgia - Dormant Projects 67 Fibromyalgia - Discontinued Products 68 Fibromyalgia - Product Development Milestones 69 Featured News & Press Releases 69 Jan 06, 2015: Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia 69 Sep 29, 2014: Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia 69 May 12, 2014: Tonix Pharmaceuticals Completes Enrollment in BESTFIT Trial of TNX-102 SL for Fibromyalgia 70 Apr 30, 2014: Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia 71 Dec 10, 2013: Tonix Pharmaceuticals Announces the Enrollment of Completers From the BESTFIT Trial Into a 12-Month Open-Label Extension Study 72 Nov 26, 2013: Tonix Pharmaceuticals to Present at the Oppenheimer Healthcare Conference 72 Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013 73 Sep 16, 2013: Tonix Pharmaceuticals Initiates Enrollment in Phase 2b BESTFIT Trial of TNX-102 SL in Fibromyalgia Patients 73 Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome 74 Mar 11, 2013: Tonix Completes Pre-Phase III Meeting With FDA For TNX-102 SL In Fibromyalgia 74 Appendix 76 Methodology 76 Coverage 76 Secondary Research 76 Primary Research 76 Expert Panel Validation 76 Contact Us 77 Disclaimer 77
List of Tables Number of Products under Development for Fibromyalgia, H1 2015 8 Number of Products under Development for Fibromyalgia - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 11 Number of Products under Investigation by Universities/Institutes, H1 2015 12 Comparative Analysis by Late Stage Development, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Comparative Analysis by Early Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Investigation by Universities/Institutes, H1 2015 17 Fibromyalgia - Pipeline by Collegium Pharmaceutical, Inc., H1 2015 18 Fibromyalgia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 19 Fibromyalgia - Pipeline by Eli Lilly and Company, H1 2015 20 Fibromyalgia - Pipeline by Merck & Co., Inc., H1 2015 21 Fibromyalgia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 22 Fibromyalgia - Pipeline by SWITCH Biotech LLC, H1 2015 23 Fibromyalgia - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 24 Fibromyalgia - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 25 Assessment by Monotherapy Products, H1 2015 26 Number of Products by Stage and Target, H1 2015 28 Number of Products by Stage and Mechanism of Action, H1 2015 30 Number of Products by Stage and Route of Administration, H1 2015 32 Number of Products by Stage and Molecule Type, H1 2015 34 Fibromyalgia Therapeutics - Recent Pipeline Updates, H1 2015 53 Fibromyalgia - Dormant Projects, H1 2015 67 Fibromyalgia - Discontinued Products, H1 2015 68
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
